Dana-Farber Cancer Institute (DFCI) — Boston, Massachusetts

Dana-Farber Cancer Institute (DFCI) is a clinical research site located in Boston, Massachusetts, United States 02215.

Crixeo Health Trust Score: 78/100 (FAIR). This profile has not yet been claimed by the site owner.

Dana-Farber Cancer Institute (DFCI) has participated in 16 clinical trials with 5 currently active.

Therapeutic areas: Glioblastoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma.

Sponsors: Philogen S.p.A., Phanes Therapeutics, ImaginAb, Inc..

Sponsor Feasibility Report

Trust Score: 78/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana-Farber Cancer Institute (DFCI)?

Dana-Farber Cancer Institute (DFCI) has a Crixeo Trust Score of 78/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana-Farber Cancer Institute (DFCI) conducted?

Dana-Farber Cancer Institute (DFCI) has 16 clinical trials on record, with 5 currently active. Their work covers Glioblastoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma.

Is Dana-Farber Cancer Institute (DFCI) accredited by Crixeo Health?

Yes — Dana-Farber Cancer Institute (DFCI) holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Dana-Farber Cancer Institute (DFCI)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.